Literature DB >> 30642220

p16 Influence on Laryngeal Squamous Cell Carcinoma Relapse and Survival.

Alvaro Sánchez Barrueco1, Fernando González Galán1, José Miguel Villacampa Aubá1, Gonzalo Díaz Tapia1, Sofía Fernández Hernández2, Cristina Martín-Arriscado Arroba3, Carlos Cenjor Español1, Carlos Almodóvar Álvarez4.   

Abstract

OBJECTIVE: (1) To identify p16 protein in laryngeal squamous cell carcinoma (LSCC) specimens and to correlate it with the presence of human papillomavirus (HPV) found in these specimens from a previous study. (2) To analyze p16 impact on 10-year overall and disease-free survival. STUDY
DESIGN: Retrospective case series with oncologic database chart review.
SETTING: Academic tertiary care hospital.
SUBJECTS: A total of 123 samples of LSCC (taken from the glottis only) from patients treated with primary surgical resection between 1977 and 2005.
METHODS: p16 protein expression was analyzed through immunohistochemistry and compared with the presence of HPV established in our previous studies. Results were compared with histologic, clinicopathologic, and survival parameters, with a 10-year follow-up.
RESULTS: Of the samples, 39.02% were positive for p16, but only 11.38% were positive for both p16 and HPV. The p16+ cohort showed a significant improvement in disease-free survival ( P = .0022); statistical significance was not achieved for overall survival. p16+ cases had fewer relapses over time, with no relapses after a 2-year follow-up. Age at the time of diagnosis and tobacco consumption were the only epidemiologic factors that influenced overall survival.
CONCLUSION: The expression of p16 protein was a beneficial prognostic factor for disease-free survival among patients with LSCC of the glottis, with no relapses after a 2-year follow-up.

Entities:  

Keywords:  disease-free survival; larynx; p16; relapse; squamous cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 30642220     DOI: 10.1177/0194599818821910

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  7 in total

1.  Potential ferroptosis-related diagnostic and prognostic biomarkers in laryngeal cancer.

Authors:  Zao Ji; Zhiyao Fang; Xue Dong; Jia Wang; Xianyao Wan; Aihui Yan
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-07-12       Impact factor: 3.236

2.  HPV in non-oropharyngeal head and neck cancer: does it matter?

Authors:  Nicole C Schmitt
Journal:  Ann Transl Med       Date:  2020-09

3.  Intraparotid lymph node metastasis from a nasal septal carcinoma: an unusual source of the unknown primary.

Authors:  Andrew John Williamson; Matthew Haywood; Zaid Awad
Journal:  BMJ Case Rep       Date:  2020-02-25

4.  Different patterns of p16INK4a immunohistochemical expression and their biological implications in laryngeal squamous cell carcinoma.

Authors:  Camelia Sidonia Lazăr; Alina Simona Şovrea; Carmen Georgiu; Doiniţa Crişan; Ştefan Claudiu Mirescu; Marcel Cosgarea
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

5.  HPV Status as Prognostic Biomarker in Head and Neck Cancer-Which Method Fits the Best for Outcome Prediction?

Authors:  Jan Philipp Kühn; Wendelin Schmid; Sandrina Körner; Florian Bochen; Silke Wemmert; Hugo Rimbach; Sigrun Smola; Julia Caroline Radosa; Mathias Wagner; Luc G T Morris; Victoria Bozzato; Alessandro Bozzato; Bernhard Schick; Maximilian Linxweiler
Journal:  Cancers (Basel)       Date:  2021-09-21       Impact factor: 6.639

6.  Role of P16 Expression in the Prognosis of Patients With Laryngeal Cancer: A Single Retrospective Analysis.

Authors:  Eugenia Allegra; Maria Rita Bianco; Chiara Mignogna; Rosario Caltabiano; Maria Grasso; Lidia Puzzo
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  Prevalence of HPV Infection and p16INK4a Overexpression in Surgically Treated Laryngeal Squamous Cell Carcinoma.

Authors:  Roberto Gallus; Tarik Gheit; Dana Holzinger; Marco Petrillo; Davide Rizzo; Gianluigi Petrone; Francesco Miccichè; Gian Carlo Mattiucci; Damiano Arciuolo; Giampiero Capobianco; Giovanni Delogu; Vincenzo Valentini; Massimo Tommasino; Francesco Bussu
Journal:  Vaccines (Basel)       Date:  2022-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.